Long-term follow-up of cipaglucosidase alfa/miglustat in ambulatory patients with Pompe disease: an open-label Phase I/II study (ATB200-02)

Barry J. Byrne,[1] Benedikt Schoser,[2] Priya Kishnani,[3] Drago Bratkovic,[4] Paula R. Clemens,[5] Ozlem Goker-Alpan,[6] Xue Ming,[7] Mark Roberts,[8] Matthias Vorgerd,[9] Kumaraswamy Sivakumar,[10] Ans T. van der Ploeg,[11] Mitchell Goldman,[12] Jacquelyn Wright,[12] Fred Holdbrook,[12] Vipul Jain,[12] Sheela Sitaraman,[12] Yasmine Wasfi,[12] Tahseen Mozaffar[13]

[1]University of Florida, Gainesville, FL, USA; [2]Friedrich-Baur-Institut, Neurologische Klinik, Ludwig-Maximilians-Universität München, Munich, Germany; [3]Duke University Medical Center, Durham, NC, USA; [4]PARC Research Clinic, Royal Adelaide Hospital, Adelaide, SA, Australia; [5]Department of Neurology, University of Pittsburgh School of Medicine, Division Chief, Neurology, Medical Service Line, VA Pittsburgh Healthcare System, Pittsburgh, PA, USA; [6]Lysosomal and Rare Disorders Research and Treatment Center, Fairfax, VA, USA; [7]Neurology, Rutgers New Jersey Medical School, Newark, NJ, USA; [8]Salford Royal NHS Foundation Trust, Salford, UK; [9]Department of Neurology, University Hospital Bergmannsheil, Heimer Institute for Muscle Research, Bochum, Germany; [10]Neuromuscular Clinic and Research Center, Phoenix, AZ, USA; [11]Erasmus MC University Medical Center, Rotterdam, Netherlands; [12]Amicus Therapeutics, Inc., Philadelphia, PA, USA; [13]University of California, Irvine, CA, USA

INTRODUCTION

- Pompe disease is a rare lysosomal disorder characterized by progressive loss of muscle and respiratory function due to acid α-glucosidase (GAA) deficiency.[1,2]
- Enzyme replacement therapy (ERT) with recombinant human GAA (rhGAA), alglucosidase alfa, is the first approved treatment for the disease[3]
  - While alglucosidase alfa has been shown to improve prognosis,[4] some patients do not respond, and many do not show a sustained benefit;[5] thus, substantial unmet clinical needs remain.[5]
- Cipaglucosidase alfa plus miglustat is an investigational, two-component therapy for Pompe disease comprised of cipaglucosidase alfa, a novel bis-mannose-6-phosphate-enhanced rhGAA, administered in conjunction with miglustat, an enzyme stabilizer.[6,7]
- Results from the PROPEL study, a 52-week, Phase III study of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in patients with Pompe disease were recently published; the open-label extension of this study is ongoing.[7]
- Data from a Phase I/II study (ATB200-02) may provide a further understanding of the long-term effect of this investigational therapy.

OBJECTIVE

- ATB200-02 (NCT02675465) is an ongoing, open-label, Phase I/II clinical trial that aimed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of cipaglucosidase alfa plus miglustat in adults with Pompe disease.
- Here, we report up to 36 months of efficacy and safety data for ambulatory patients with Pompe disease in the ATB200-02 study.

METHODS

- The ATB200-02 study is conducted in 17 centers across 6 countries, with 4 cohorts of patients enrolled at staggered timepoints.
- The study design is presented in **Figure 1**.

Figure 1. Phase I/II ATB200-02 study design

*With 20 mg/kg alglucosidase alfa Q2W. Q2W, every 2 weeks.

- A summary of the endpoints and cohorts we report is presented in **Table 1**.
- Available data for cohort 2, non-ambulatory ERT-experienced patients, are presented in the Supplement, which is available via quick response (QR) code.
- Data were analyzed using descriptive statistics.

Table 1. Summary of endpoints and cohorts reported

Assessments	ERT experienced*		ERT naïve Cohort 3
	Cohort 1 (2–6 years)	Cohort 4 (≥7 years)	
Motor function • 6MWD	Pooled data		✓
Respiratory function • FVC	Pooled data		✓
Muscle strength • MMT lower extremity score	Pooled data		✓
Biomarkers • Hex4 and CK	Pooled data		✓
Safety	Pooled data		✓
	Pooled data		

*With 20 mg/kg alglucosidase alfa Q2W. 6MWD, 6-minute walk distance; CK, creatine kinase; FVC, forced vital capacity; Hex4, glucose tertasaccharide; MMT, manual muscle test.

RESULTS

Patients

- Baseline characteristics were representative of the Pompe disease population (**Table 2**).
- Due to the staggered timing of patient enrollment, the number of patients with data currently available decreases at later timepoints in this ongoing study.

Table 2. Baseline characteristics and patient disposition

	ERT experienced		ERT naïve Cohort 3 n=6
	Cohort 1 2–6 years prior ERT n=11	Cohort 4 ≥7 years prior ERT n=6	
Baseline characteristics			
Median (range) age, years	49.4 (28–66)	40.8 (20–65)	49.3 (24–65)
Sex, M:F	9:2	2:4	1:5
Mean (SD) time on alglucosidase alfa, years	4.7 (1.4)	9.4 (1.2)	N/A*
Mean (SD) 6MWD, m	397.2 (96.8)	387.3 (161.3)	396.0 (75.2)
Mean (SD) sitting FVC, % predicted	52.6 (13.9)	65.3 (21.1)	55.8 (19.1)
Mean (SD) MMT lower extremity score	31.8 (1.9)	27.3 (3.7)	29.0 (1.7)
Patient disposition			
Ongoing in study, n (%)	9 (82)	6 (100)	6 (100)

*1 ERT-naïve patient had received 1 dose of alglucosidase alfa >6 months prior to study entry. m, meters; M:F, male:female; N/A, not applicable; SD, standard deviation.

Motor function

- ERT-experienced cohorts showed durable mean improvements from baseline in 6MWD up to 36 months (**Figure 2A**).
- After 12, 24 and 36 months of follow-up, 6MWD improved numerically from baseline in 13/16, 8/10, and 6/8 ERT-experienced patients, respectively.
- The ERT-naïve cohort showed durable mean improvements from baseline in 6MWD up to 36 months (**Figure 2B**).
- After 12, 24 and 36 months of follow-up, 6MWD improved numerically from baseline in 6/6, 5/5, and 4/5 ERT-naïve patients, respectively.

Figure 2. CFBL in 6MWD in (A) ERT-experienced and (B) ERT-naïve patients



Respiratory function

- Mean CFBL in FVC was generally stable for up to 36 months of follow-up in ERT-experienced cohorts (**Figure 3A**).
- After 12, 24 and 36 months of follow-up, FVC improved (>3% points) or remained stable (±3% points) from baseline in 9/16, 6/10, and 6/8 ERT-experienced patients, respectively.
- Mean CFBL in FVC improved numerically from baseline for up to 36 months of follow-up in the ERT-naïve cohort (**Figure 3B**).
- After 12, 24 and 36 months of follow-up, FVC improved (>3% points) or remained stable (±3% points) from baseline in 5/6, 5/5, and 5/5 ERT-naïve patients, respectively.

Figure 3. CFBL in FVC in (A) ERT-experienced and (B) ERT-naïve patients



*One patient in the ERT-naïve cohort experienced a large drop in % predicted FVC at month 21, which returned to previous levels at the following visit (month 24).

Muscle strength

- Mean change in MMT lower extremity score improved numerically from baseline and improvements were maintained for up to 36 months of follow-up in both ERT-experienced and ERT-naïve cohorts (**Figure 4**).

Figure 4. CFBL in MMT lower extremity score in (A) ERT-experienced and (B) ERT-naïve patients

Biomarkers

- During 36 months of follow-up, cipaglucosidase alfa plus miglustat was generally associated with mean reductions from baseline in urine Hex4, with greater reductions in ERT-naïve patients (**Figure 5A**).
- After 12, 24 and 36 months of follow-up, Hex4 levels decreased numerically from baseline in 13/16, 6/10, and 3/4 ERT-experienced patients, and in 5/6, 4/5, and 1/1 ERT-naïve patients, respectively.
- During 36 months of follow-up, cipaglucosidase alfa plus miglustat was associated with either stable levels of, or mean reductions from baseline, in plasma CK, with greater reductions in ERT-naïve patients (**Figure 5B**).
- After 12, 24 and 36 months of follow-up, CK levels decreased numerically from baseline in 10/15, 6/11, and 4/4 ERT-experienced patients, and in 6/6, 5/5, and 1/1 ERT-naïve patients, respectively.

Figure 5. Percentage CFBL in Hex4 and CK levels



Safety

- **Table 3** presents a summary of treatment-emergent adverse events (TEAEs).
- Mean (SD) duration of treatment was 37.2 (14.48), 19.9 (4.13) and 36.9 (12.14) months in cohorts 1 (prior ERT 2–6 years), 4 (prior ERT ≥7 years) and 3 (ERT naive), respectively.
- The most common TEAEs included fall, nasopharyngitis and arthralgia; most TEAEs were mild or moderate in severity and did not lead to study withdrawal.

Table 3. Summary of TEAEs

	ERT experienced n=17	ERT naïve n=6	Overall N=23
TEAEs, n (%)	17 (100)	6 (100)	23 (100)
TEAEs potentially related to treatment	11 (65)	3 (50)	14 (61)
Serious TEAEs	3 (18)	2 (33)	5 (22)
Serious TEAEs potentially related to treatment	1 (6)	1 (17)	2 (9)
TEAEs leading to study withdrawal	1 (6)*	0 (0)	1 (4)
TEAEs leading to death	0 (0)	0 (0)	0 (0)
IARs	7 (41)	2 (33)	9 (39)

TEAEs have an onset date on or after first dose of study drug. *Diffuse large B-cell lymphoma. IAR, infusion-associated reaction.

Limitations

- As might be expected for a Phase I/II study of a rare disease therapy, the sample size was relatively small.
- The heterogenous nature of Pompe disease, spanning a wide spectrum of manifestations, disease severity, rates of progression, and responses to treatment, may have introduced variability into the dataset.
- Data were analyzed descriptively, with no statistical comparisons made.

CONCLUSIONS

- Results from up to 36 months of follow-up in ambulatory patients from the ATB200-02 study of cipaglucosidase alfa plus miglustat showed:
  - ERT-experienced patients had durable mean improvements from baseline in motor function that were sustained for up to 36 months of follow-up, while respiratory function was stable and maintained over the same period: an improvement relative to the expected decline in many patients receiving long-term ERT[5]
  - ERT-naïve patients showed durable mean improvements from baseline in motor and respiratory function that were sustained for up to 36 months of follow-up
  - Mean levels of two biomarkers, Hex4 and CK, were either stable or decreased from baseline up to 36 months of follow-up, with decreases most notable in the ERT-naïve cohort
  - The safety profile of cipaglucosidase alfa plus miglustat was similar to that reported for alglucosidase alfa.[4]

Acknowledgments

The authors thank the patients, their families, and Pompe disease patient organizations, as well as the ATB200-02 study investigators.

This presentation shares information about Amicus Therapeutics' investigational therapy, cipaglucosidase alfa/miglustat, which is in development for the treatment of Pompe disease. This investigational therapy is not approved by any regulatory agency at this time.

Medical writing assistance was provided by Anna Campbell, PhD, CMPP, at Cence (an AMICULUM agency®) and was funded by Amicus Therapeutics, Inc.

The presenter, Professor Barry J. Byrne, is the co-founder of Aavanti Bio, Inc.

References

1. Hers HG. *Biochem J* 1963;86:11–6.
2. Kishnani PS *et al. Genet Med* 2006;8:267–88.
3. Genzyme. Lumizyme prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125291s151lbl.pdf (accessed Feb 2022).
4. van der Ploeg AT *et al. N Engl J Med* 2010;362:1396–406.
5. Harlaar L *et al. Neurology* 2019;93:e1756–67.
6. Xu S *et al. JCI Insight* 2019;4:e125358.
7. Schoser B *et al. Lancet Neurol* 2021;20:1027–37.

Poster PDF

Please scan these QR codes with your smartphone camera or app to obtain PDF copies of this poster and supplementary material.

Copies of materials obtained through QR codes are for personal use only and may not be reproduced without permission from the Muscular Dystrophy Association (MDA) and the authors of this presentation.

Supplement

This study was supported by Amicus Therapeutics, Inc.

Presented at the 2022 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference; Nashville, TN, USA and online; March 13–16.